Epogen (epoetin alfa) / Amgen - LARVOL DELTA

Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial (ASH 2025) - P3 | "Background :In the phase 3 COMMANDS trial (NCT03682536) evaluating pts with ESA-naive transfusion-dependent(TD) LR-MDS, luspatercept was superior to epoetin alfa (EA) in achieving red blood cell-transfusionindependence (RBC-TI) ≥12 weeks (wks) and demonstrated a more durable clinical benefit. Pts with less severe disease characteristics, reflective of an earlier disease stage, derive greater clinicalbenefit from treatment than those with more advanced characteristics. Pts on luspatercept vs EAdemonstrated higher response rates and longer duration of response regardless of disease stage, furthersupporting its role as a preferred first-line therapy in LR-MDS."

Clinical • Retrospective data • Hematological Malignancies • Myelodysplastic Syndrome

A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial) (clinicaltrials.gov) - P2 | N=270 | Not yet recruiting | Sponsor: National Cancer Institute (NCI)

New P2 trial • Anemia • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Myelodysplastic Syndrome • Oncology

Audit to investigate haemoglobin levels following switch of ESA brand for haemodialysis patients. (UKKW 2026) - "Erythropoietin stimulating agents (ESAs) such as Eprex (epoetin alfa) are used to manage haemoglobin (Hb) anaemia of CKD. Overall, it is evident that the switch from Eprex to Retacrit was a success in the Trust as patient safety wasn't compromised. This audit should provide further evidence to wider Trusts to consider ESA alternatives as a cost-savings strategy and potentially improve clinical outcomes for haemodialysis on ESAs as demonstrated in this cohort."

Clinical • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

EPOBLAIV25011: Study in healthy volunteers to compare the blood levels after epoetin alfa (Blau EPO) and Erypo, administered as a single intravenous injection as well as safety, tolerability and the effects on certain blood values. (clinicaltrialsregister.eu) - P1 | N=64 | Not yet recruiting | Sponsor: Blau Farmaceutica S.A.

New P1 trial • Anemia • Chronic Kidney Disease • Hematological Disorders • Renal Disease

VOICE: Vafseo Outcomes In-Center Experience (clinicaltrials.gov) - P3 | N=2200 | Active, not recruiting | Sponsor: USRC Kidney Research | Recruiting ➔ Active, not recruiting

Enrollment closed • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Clinical Approach to Relapsed or Refractory Lower-Risk Myelodysplastic Syndromes (ICKSH 2026) - "In the phase 3 COMMANDS trial (ESA -naïve TD LR -MDS; IPSS -R very low/low/intermediate; sEPO <500 U/L; <5% blasts; del(5q) excluded), luspatercept significantly improved the primary endpoint (RBC -TI for ≥12 weeks with concurrent mean hemoglobin [Hb] increase ≥1.5 g/dL during weeks 1–24) versus epoetin alfa (60.4% vs 34.8%; p<0.0001). Evidence -based sequencing begins with early ESA use when appropriate, transitions to luspatercept when response is lost, but consider this agent not only in R/R cases, but also as an effective and durable first -line option (with subgroup -consistent benefit), for TD ESA -naïve LR -MDS who do not have probability to respond to ESAs and incorporates imetelstat as a potentially disease -modifying therapy in ESA -failed/ESA -ineligible and lus patercept -failed TD LR - MDS , especially if with high transfusion burden . Molecularly targeted agents and cytogenetically defined approaches (e.g., lenalidomide in del(5q) ,..."

Clinical • Cardiovascular • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Neutropenia • Thrombocytopenia • ACVR2A • IDH1 • IDH2 • SF3B1

A Rare Case of Waldenström's Macroglobulinemia Presenting as Nephrotic Syndrome in Progressive CKD (NKF-SCM 2026) - "He also developed refractory anemia (Hb <9.5 g/dL) despite escalating epoetin alfa...The patient began treatment with rituximab and bendamustine RESULTS/CASE DISCUSSION WM is an uncommon but important cause of nephrotic syndrome...In this case, new nephrotic-range proteinuria prompted reevaluation and led to the correct diagnosis. Early recognition is essential, as chemotherapy targeting WM can improve proteinuria and stabilize kidney function CONCLUSION This case illustrates WM presenting as nephrotic syndrome and progressive CKD, emphasizing the need for heightened suspicion for monoclonal gammopathy-related renal disease when features are atypical or unexplained"

Clinical • Cardiovascular • Chronic Kidney Disease • Glomerulonephritis • Hematological Disorders • Hematological Malignancies • Hypertension • Immunology • Infectious Disease • Lymphoma • Lymphoplasmacytic Lymphoma • Monoclonal Gammopathy • Multiple Myeloma • Nephrology • Non-Hodgkin’s Lymphoma • Pneumonia • Renal Disease • Respiratory Diseases • Waldenstrom Macroglobulinemia

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study. (PubMed, Am J Hematol) - P3 | "Here we report red blood cell (RBC) transfusion response analysis based on somatic mutations profile and disease risk for patients treated with luspatercept or epoetin alfa in the COMMANDS trial. Luspatercept represents an effective treatment option in various mutational backgrounds in LR MDS. Trial Registration: ClinicalTrials.gov Identifier: NCT03682536."

Journal • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Oncology • SF3B1

EPO-PRETAR: A Trial Testing Early Vs Late Onset of EPO Alfa Treatment in Lower Risk MDS (clinicaltrials.gov) - P3 | N=124 | Recruiting | Sponsor: Groupe Francophone des Myelodysplasies | Not yet recruiting ➔ Recruiting

Enrollment open • Anemia • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Oncology

EPO-PRETAR: A Trial Testing Early Vs Late Onset of EPO Alfa Treatment in Lower Risk MDS (clinicaltrials.gov) - P3 | N=124 | Not yet recruiting | Sponsor: Groupe Francophone des Myelodysplasies

New P3 trial • Anemia • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Oncology

EPO-PRETAR: A Trial Testing Early Vs Late Onset of EPO Alfa Treatment in Lower Risk MDS (clinicaltrials.gov) - P3 | N=124 | Active, not recruiting | Sponsor: Groupe Francophone des Myelodysplasies | Recruiting ➔ Active, not recruiting | Trial completion date: May 2024 ➔ Oct 2028

Enrollment closed • Trial completion date • Anemia • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Oncology

EPO-PRETAR: A Trial Testing Early Vs Late Onset of EPO Alfa Treatment in Lower Risk MDS (clinicaltrials.gov) - P3 | N=124 | Recruiting | Sponsor: Groupe Francophone des Myelodysplasies | Trial completion date: Oct 2021 ➔ May 2024 | Trial primary completion date: Oct 2019 ➔ May 2022

Trial completion date • Trial primary completion date • Anemia • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Oncology

ELRiSE MDS: A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (clinicaltrials.gov) - P3 | N=300 | Recruiting | Sponsor: Takeda | Not yet recruiting ➔ Recruiting

Enrollment open • Anemia • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Oncology

Use of Epoetin Alfa for Anemia of Chronic Disease in a Jehovah's Witness Teenager With Disseminated Coccidioidomycosis: A Case Report. (PubMed, Cureus) - "Because blood transfusion was declined, epoetin alfa was administered as a transfusion-sparing strategy prior to surgical intervention. This case highlights a potential role of epoetin alfa as an alternative strategy for managing infection-related anemia in select patients when transfusion is not an option."

Journal • Anemia • Hematological Disorders • Infectious Disease • Inflammation • Pediatrics • Respiratory Diseases

ELRiSE MDS: A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (clinicaltrials.gov) - P3 | N=300 | Not yet recruiting | Sponsor: Takeda

New P3 trial • Anemia • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Oncology

Copper Replacement: A Life-Saving Treatment. (PubMed, Cureus) - "Despite receiving 20,000 units of epoetin alfa three times weekly and intravenous iron supplementation, her hemoglobin level failed to improve...This case illustrates the importance of thinking about copper deficiency in a patient with a history of gastric bypass. It could be lifesaving for a patient who is a Jehovah's Witness."

Journal • Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Chemotherapy-Free Achievement of Minimal Residual Disease in a Jehovah's Witness Patient With Ph-Negative B-ALL. (PubMed, Am J Case Rep) - "Supportive care included epoetin alfa, romiplostim, iron, and vitamin supplementation. CONCLUSIONS This is the first known reported case that demonstrates the feasibility and effectiveness of a chemotherapy-free induction strategy using inotuzumab and blinatumomab for frontline treatment of Ph-negative B-ALL in Jehovah's Witness patients. It shows that MRD negativity can be safely achieved without cytotoxic chemotherapy or transfusion support and supports the use of the ALLIANCE A041703 trial regimen as a treatment model for this unique and underserved patient group."

Journal • Minimal residual disease • Acute Lymphocytic Leukemia • Atrial Fibrillation • B Acute Lymphoblastic Leukemia • Cardiovascular • Hematological Disorders • Hematological Malignancies • Hypertension • Leukemia • Oncology

A Retrospective Study of Bloodless Administration of Cellular Therapy in a Community Medical Center in an Outpatient and Inpatient setting: Patient Characteristics and Outcomes (TCT-ASTCT-CIBMTR 2026) - "Tranexamic acid, romiplostim and Epoetin alfa-epbx support are allowed. In this retrospective cohort of patients receiving ASCT or CarT under a bloodless therapy protocol, we have seen excellent cell recovery, toxicity, and 30-day mortality outcomes in both BL-ASCT and BL-CarT recipients. There is a trend for increased hospitalization in BLCT, largely due to inpatient administration of product and monitoring. We suggest that patients who cannot receive blood products should be considered for BL-ASCT or BL-CarT."

Retrospective data • Hematological Malignancies • Infectious Disease

[VIRTUAL] The Commands Trial: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low-, Low-, or Intermediate-Risk MDS in Erythropoiesis Stimulating Agent-Naive Patients Who Require RBC Transfusions (ASH 2020) - P3 | "Recent studies of epoetin alfa and darbepoetin alfa have demonstrated efficacy among patients with LR-MDS, but the patient population in whom a clinically significant effect is seen may be limited (Fenaux P, et al...Exclusion criteria include prior use of ESAs (≤ 2 doses of prior epoetin alfa permitted if ≥ 8 weeks from randomization date and sEPO confirmed as ≤ 500 U/L), granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF), unless given for the treatment of febrile neutropenia; disease-modifying agents (e.g. lenalidomide), or hypomethylating agents; and presence of del(5q) cytogenetic abnormality...Key secondary endpoints include duration of RBC-TI, change in Hb levels, achievement of HI-E response per International Working Group (IWG) 2006 criteria, and safety. The COMMANDS trial is registered at ClinicalTrials.gov (NCT03682536) and EudraCT (number 2017-003190-34)."

Clinical • P3 data • Anemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Neutropenia • Oncology • CSF2 • EPO • SF3B1

Preemptive Tocilizumab with Bispecific Antibodies in Relapsed-Refractory Multiple Myeloma: A Case Series (TCT-ASTCT-CIBMTR 2026) - "Teclistamab (Tec), Talquetamab (Tal), and Elranatamab (Elra) are bispecific antibodies (BsAbs) approved for relapsed-refractory Multiple Myeloma (RRMM) which target CD3 on T- cells and either BCMA or GPRC5D, depending on the BsAb...The only incident of CRS occurred with a single patient who developed grade 1 CRS on C1D3 which resolved after one dose dexamethasone 10 mg...Supportive care was given during treatment including filgrastim to maintain absolute neutrophil 1.00 K/mcl, epoetin alfa to maintain hemoglobin above 10g/dl, and romiplostim to maintain platelets above 50 K/mcl...3. Evaluate the potential role and clinical impact of preemptive tocilizumab administration in reducing the incidence and severity of CRS without compromising therapeutic response in patients receiving bispecific antibodies."

Clinical • Hematological Malignancies • Infectious Disease • Multiple Myeloma • IL6

LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY (EHA 2023) - P3 | "Luspatercept demonstrated superiority over epoetin alfa with clinically meaningful improvements in RBC-TIand HI-E rates in ESA-naiveLR-MDS pts who requiretransfusions.Luspatercept showed morefavorable outcomes compared to epoetin alfa across a spectrum of known MDS mutations.Luspatercept safety profile was comparable with previous reports; no new safety events wereidentified.Luspatercept may transform thecurrent landscape by establishing a new standard of tx for ESA-naive pts with transfusion dependent LR-MDS. Keywords: Mutation analysis, Myelodysplastic syndrome,Erythropoieisis, Clinical trial"

Clinical • P3 data • Tumor mutational burden • Acute Myelogenous Leukemia • Anemia • Cardiovascular • Fatigue • Hematological Disorders • Hematological Malignancies • Hypertension • Myelodysplastic Syndrome • Oncology • ASXL1 • DNMT3A • IDH2 • SF3B1 • TET2 • TMB • U2AF1

Longitudinal Safety of Luspatercept in the Treatment of Anemia in Patients with Myelofibrosis: Results from the ACE-536-MF-001 Study (ASH 2023) - P2 | "Methods Pts were enrolled into 4 cohorts based on transfusion dependence (TD) and stable ruxolitinib (RUX) treatment – cohort 1: NTD, no RUX; cohort 2: TD, no RUX; cohort 3A: NTD, RUX; cohort 3B: TD, RUX...Results In the safety population (N = 95; cohort 1, n = 22; cohort 2, n = 14; cohort 3A, n = 21; cohort 3B, n = 38), the most frequently used prior medications for anemia treatment were erythropoiesis-stimulating agents (23.2%, most frequently epoetin alfa [14.7%]), followed by danazol (11.6%), lenalidomide (2.1%), and thalidomide (1.1%)...In addition to benefits in anemia, the safety profile of LUSPA allowed most pts receiving RUX to maintain or increase their RUX dose, supporting maintenance of Janus kinase inhibitor therapy for adequate disease control of MF. Study support: Bristol Myers Squibb."

Clinical • Anemia • Beta-Thalassemia • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Hypertension • Infectious Disease • Inflammation • Ischemic stroke • Musculoskeletal Pain • Myelodysplastic Syndrome • Myelofibrosis • Oncology • Pain • Pneumonia • Renal Disease • Respiratory Diseases • Septic Shock

Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial (ASH 2023) - P3 | "Results of this full analysis confirm the findings from the interim analysis; RBC-TI duration and erythroid responses achieved with luspatercept are superior compared with epoetin alfa. Luspatercept safety results were consistent with previous MDS studies. These data show that luspatercept could represent a new standard of care for pts with TD LR-MDS."

Clinical • Acute Myelogenous Leukemia • Anemia • Cardiovascular • Fatigue • Hematological Disorders • Hematological Malignancies • Hypertension • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Novel Coronavirus Disease • Oncology • SF3B1

Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent–Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial (ASH 2024) - P3 | "Progression rates to high-risk MDS and AML were low in both treatment arms. These data support luspatercept as the treatment of choice in TD ESA-naive pts with lower-risk MDS."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • SF3B1

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. (PubMed, Lancet) - P3 | "In this interim analysis, luspatercept improved the rate at which red blood cell transfusion independence and increased haemoglobin were achieved compared with epoetin alfa in ESA-naive patients with lower-risk myelodysplastic syndromes. Long-term follow-up and additional data will be needed to confirm these results and further refine findings in other subgroups of patients with lower-risk myelodysplastic syndromes, including non-mutated SF3B1 or ring sideroblast-negative subgroups."

Journal • P3 data • P3 data: top line • Acute Myelogenous Leukemia • Cardiovascular • Fatigue • Hematological Disorders • Hematological Malignancies • Hypertension • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Neutropenia • Novel Coronavirus Disease • Oncology • Pain • Pneumonia • Pulmonary Disease • Respiratory Diseases • Thrombocytopenia • SF3B1